946594-20-3

Upstream product

• 849106-47-4 4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol L-(+) tartrate salt 
• 106-39-8 bromochlorobenzene 
• 690660-21-0 4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol 
• 475085-56-4 4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 324769-06-4 tert-butyl 3,3-dimethyl-4-oxopiperidine-1-carboxylate 
• 690660-22-1 (S)-4-(4-chlorophenyl)-3,3-dimethylpiperidin-4-ol 
• 22838-58-0 Boc-D-Val-OH 

Downstream Products

• 946593-51-7 (R)-2-amino-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methylbutan-1-one hydrochloric acid salt 
• 946593-15-3 1-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-cyclopentylurea 
• 946588-02-9 (R)-1-sec-butyl-3-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)urea 
• 946585-25-7 N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-sulfamoylbenzamide 
• 946592-68-3 N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxy-3-methylbutanamide 
• 946590-21-2 C₂₃H₃₃ClN₂O₃ 
• 946587-15-1 (1R,3S)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxycyclopentanecarboxamide 
• 946587-14-0 (1S,3R)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxycyclopentanecarboxamide 
• 946587-13-9 (1S,3S)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3-hydroxycyclopentanecarboxamide 
• 946594-19-0 BMS-457 
• 1443512-83-1 C₂₄H₃₆ClN₃O₃ 
• 1443512-82-0 C₂₄H₃₆ClN₃O₃ 

Relevant academic research and scientific papers

Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis

High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis.

The discovery of BMS-457, a potent and selective CCR1 antagonist

A series of compounds which exhibited good human CCR1 binding and functional potency was modified resulting in the discovery of a novel series of high affinity, functionally potent antagonists of the CCR1 receptor. Issues of PXR activity, ion-channel pote

PRODRUGS OF A PIPERIDINYL DERIVATIVE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well a

PIPERIDINYL DERIVATIVE AS A MODULATOR OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune